<DOC>
	<DOCNO>NCT01466790</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety TMC435 plus PSI-7977 ( GS7977 ) without ribavirin patient chronically infect genotype 1 hepatitis C virus ( HCV ) respond prior peginterferon/ribavirin therapy HCV treatment-naive ( patient never receive treatment HCV infection ) .</brief_summary>
	<brief_title>A Study TMC435 Combination With PSI-7977 ( GS7977 ) Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy HCV Treatment-Naive Patients</brief_title>
	<detailed_description>This Phase IIa , randomize ( study medication assign chance ) , open label ( people know identity intervention ) study TMC435 plus PSI-7977 ( GS7977 ) without ribavirin . The study consist screen phase ( 6 week ) ; treatment phase ( 12 24 week period ) ; posttreatment phase ( follow-up period Week 48 ) . Approximately 180 patient enrol study . Patients sequentially enrol two cohort study . Cohort 1 ( 90 patient ) include patient without advanced hepatic fibrosis respond previous PegIFN/ribavirin therapy Cohort 2 ( 90 patient ) include patient advanced hepatic fibrosis respond previous PegIFN/ribavirin therapy HCV treatment-naive . Safety evaluate throughout study include evaluation adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination . The entire study duration participant approximately 48 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Chronic genotype 1 hepatitis C virus ( HCV ) infection Plasma HCV RNA 10,000 IU/mL screen Patients Cohort 1 must null responder PegIFN/ribavirin least 1 documented previous course PegIFN/ribavirin therapy least 12 consecutive week Patients Cohort 2 must null responder PegIFN/ribavirin least 1 documented previous course PegIFN/ribavirin therapy least 12 consecutive week could also HCV treatmentnaive , mean never receive treatment approve investigational drug treatment HCV Null responders patient Cohort 1 Cohort 2 must meet defined criterion null responder , define ontreatment le 2 log10 IU/mL reduction HCV RNA baseline Week 12 recent PegIFN/ribavirin therapy Patient must liver biopsy within 3 year screen ( screen baseline visit ) patient must liver biopsy time past show Metavir F3 F4 fibrosis Must agree use 2 form effective contraception throughout study ( male female ) Has evidence hepatic decompensation Has liver disease nonHCV etiology Has infection/coinfection nongenotype 1 HCV Has coinfection Human immunodeficiency virus ( HIV ) type 1 type 2 ( HIV1 HIV2 ) ( positive HIV1 HIV2 antibody test screening ) Has coinfection hepatitis B virus ( hepatitis B surface antigen [ HBsAg ] positive ) Has history malignancy within 5 year screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>TMC435</keyword>
	<keyword>PSI-7977</keyword>
	<keyword>GS7977</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>HCV</keyword>
	<keyword>Hep C</keyword>
	<keyword>Genotype 1</keyword>
</DOC>